The board of directors of Viva Biotech Holdings announce that (i) Mr. Cheng Xueheng ("Mr. Cheng") has been appointed as the chief technology officer of the Company, primarily responsible for overseeing the Group's drug discovery technology platforms; and (ii) Mr. Xu David Daqiang ("Mr. Xu") has been appointed as the chief business officer of the Company, primarily responsible for overseeing the Group's equity-for-service (EFS) business model, with effect from August 23, 2019. Mr. Cheng, aged 64, joined Viva Biotech (Shanghai) Ltd. ("Viva Biotech Shanghai"), the principal operating subsidiary of the Group, in September 2009. Prior to joining the Group, Mr. Cheng served as vice president and chief scientist officer at Excel Research from August 2008 to August 2009. Mr. Xu jointed the Group in 2019 and has served as the chief business officer of Viva Biotech Shanghai since then. Prior to joining the Group, Mr. Xu was the vice president in charge of the Pharmaceutical Business Unit at Zhejiang Jiuzhou Pharmaceuticals Co. Ltd.